Larger Acute Phase Reactions Are Associated with Immunogenicity of an Adjuvanted Recombinant Receptor Binding Domain Protein Vaccine Against SARS-CoV-2 in Rhesus Monkeys
Open Access
Abstract
Background: Although prolonged inflammatory symptoms are an infrequent and problematic adverse effect of vaccination that can occur in some people, the transient activation of acute phase reactants (APRs) is expected with adjuvanted vaccines and helps to potentiate immune responses. Methods: This experiment examined the association between vaccine reactogenicity and immunogenicity in monkeys immunized with an adjuvanted recombinant protein including a receptor binding domain–human IgG1-Fc fusion protein (RBD-Fc) sequenced from the ancestral Wuhan strain of SARS-CoV-2. The acute inflammatory reaction to immunization was assessed by determining the decline in serum iron levels at 24 h and the increase in the neutrophil-to-lymphocyte ratio (NLR) as the adherent neutrophil pool trafficked into circulation. Results: Robust primary and secondary antibody responses were elicited. Larger decreases in serum iron and higher NLRs were associated with a stronger inhibition of RBD binding with angiotensin-converting enzyme (ACE2) when five early viral variants of SARS-CoV-2 were tested, including Wuhan, Alpha, Beta, Gamma and Delta. Inhibition of ACE2-RBD binding was less evident when the Omicron variant was tested. Individual variation in the APR was also predictive of the persistence of cell-mediated immunity based on the number of interferon-expressing mononuclear cells activated by viral antigen in ELISpot assays. Conclusions: Rapid antibody responses to primary immunization and large secondary responses to booster immunizations were elicited by this adjuvanted recombinant RBD-Fc vaccine, and our analysis affirmed the view that a transient APR can enhance antibody binding with antigen proteins.Keywords
Funding Information
- University of Wisconsin-Madison
- Lytic Solutions
This publication has 76 references indexed in Scilit:
- Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in IndiaJAMA Pediatrics, 2023
- Adverse events following COVID‐19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopeniaImmunity, Inflammation and Disease, 2023
- SARS-CoV-2 infects neurons and induces neuroinflammation in a non-human primate model of COVID-19Cell Reports, 2022
- Overview of vaccine adjuvants2022
- Recombinant protein vaccines, a proven approach against coronavirus pandemicsAdvanced Drug Delivery Reviews, 2021
- Anemia in patients with Covid-19: pathogenesis and clinical significanceClinical and Experimental Medicine, 2021
- Vaccines for Veterinarians2021
- Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, ItalyJAMA Internal Medicine, 2020
- Immunophenotyping of Rhesus CMV‐Specific CD8 T‐Cell PopulationsCytometry Part A, 2020
- Feasibility of successfully breeding rhesus macaques (Macaca mulatta) to obtain healthy infants year‐roundAmerican Journal of Primatology, 2019